S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:NYMX

Nymox Pharmaceutical (NYMX) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.19
$0.47
52-Week Range
N/A
Volume
932,700 shs
Average Volume
94,622 shs
Market Capitalization
$18.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NYMX stock logo

About Nymox Pharmaceutical (NASDAQ:NYMX) Stock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.


NYMX Stock News Headlines

Nymox Reports Completion of $2 Million Private Placement
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Nymox Reports on U.S. Patent Issuances
Nymox Pharmaceutical Corporation: NYMOX Update
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
NYMOX Update
Nymox Delisting from NASDAQ
NYMX - Nymox Pharmaceutical Corporation
Nymox Pharmaceutical (NASDAQ: NYMX)
Nymox Provides Corporate Update
NYMOX Appeals Deficiency Letter
May 2023 Market Cap Requirement Update
See More Headlines
Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Company Calendar

Last Earnings
11/14/2014
Today
9/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NYMX
Employees
3
Year Founded
N/A

Profitability

Net Income
$-6,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.01) per share

Miscellaneous

Free Float
41,637,000
Market Cap
$18.10 million
Optionable
Optionable
Beta
0.64
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Paul Averback DABP (Age 72)
    M.D., Founder, Chairman, CEO & Pres
    Comp: $660k
  • Mr. Randall J. Lanham Esq. (Age 59)
    J.D., Gen. Counsel, Sec., COO & Director
    Comp: $496.45k
  • Ms. Lin Dodd
    QA and Compliance Mang.
  • Mr. Christopher R. Riley
    Chief Financial Officer













NYMX Stock - Frequently Asked Questions

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) released its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter.

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How much money does Nymox Pharmaceutical make?

Nymox Pharmaceutical (NASDAQ:NYMX) has a market capitalization of $0.00. The biopharmaceutical company earns $-6,580,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The official website for the company is www.nymox.com. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at info@nymox.com, or via fax at 514-332-2227.

This page (NASDAQ:NYMX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -